Acute kidney injury is linked with higher mortality in hospitalized very old adults, while frailty is associated with higher injury risk across surgical cohorts. Human observational studies also link PhenoAge acceleration and clonal hematopoiesis with higher risk. A nicotinamide mononucleotide trial and a metformin trial reported as a preprint show no clear effect on acute kidney injury.
468 findings in 376 papers from 2015 to 2026, 102 of them since April 2026
“The risk of acute kidney injury was significantly lower among SGLT2i users compared with placebo [risk ratio (RR) 0.73; 95% CI 0.62-0.87].”
SGLT2 inhibitors were not clearly linked with acute kidney injury in humans (isolated surgical aortic valve replacement for nonrheumatic aortic stenosis) (6.1% vs 9.6%; HR 0.68, 95% CI 0.44–1.05).
“acute kidney injury (6.1% vs 9.6%; HR 0.68, 95% CI 0.44-1.05”
Humansisolated surgical aortic valve replacement for nonrheumatic aortic stenosis30 to 365 days after SAVR
SGLT2 inhibitors were not clearly linked with acute kidney injury in humans (continuation for 3 months after TAVI versus discontinuation, propensity-matched cohorts) (HR 0.98, 95% CI 0.79–1.20).
“with no increased risk of acute kidney injury (HR 0.98, 95% CI 0.79–1.20, p=0.82)”
Humanscontinuation for 3 months after TAVI versus discontinuation, propensity-matched cohorts1 yearn = 1,104
SGLT2 inhibitors were not clearly linked with acute kidney injury in humans (heart failure patients after TAVR, propensity score-matched cohort) (32.6% vs. 27.9%; RR 1.168 (95% CI 0.991-1.378)).
“AKI (32.6% vs. 27.9%; RR=1.168, 95% CI: 0.991-1.378, p=0.063)”
Humansheart failure patients after TAVR, propensity score-matched cohortn = 660
SGLT2 inhibitors are linked with lower acute kidney injury in humans (preoperative use within 1 year before index procedure; propensity score-matched cohort) (15.4% vs 17.7%; RR 0.870).
“Acute kidney injury at 30 days was lower with SGLT2 inhibitors (15.4% vs. 17.7%; RR 0.870, p < 0.001)”
Humanspreoperative use within 1 year before index procedure; propensity score-matched cohort30 daysn = 7,526
SGLT2 inhibitors were not clearly linked with acute kidney injury in humans (propensity-score-matched patients with type 2 diabetes undergoing TEER) (31.7% vs 32.9%).
“There were no significant differences in MACE (52.0 vs. 46.2%, P = 0.136) or AKI (31.7 vs. 32.9%, P = 0.737).”
Humanspropensity-score-matched patients with type 2 diabetes undergoing TEER1 yearn = 325
Journal of cardiovascular medicine (Hagerstown, Md.)·
SGLT2 inhibitors are linked with lower acute kidney injury in humans (compared with other second-line glucose-lowering drugs; target trial emulation) (average individual treatment effect -0.0039 (95% CI -0.0065 to -0.0014)).
“SGLT2 inhibitors were associated with a significant reduction in AKI compared with other second-line glucose-lowering drugs, with an average individual treatment effect of -0.0039 (95% CI: -0.0065 to -0.0014).”
Humanscompared with other second-line glucose-lowering drugs; target trial emulation
medRxiv : the preprint server for health sciences·Preprint
SGLT2 inhibitors are linked with lower acute kidney injury in humans (people with dementia, versus DPP4 inhibitors) (IRD -39.7 per 1000 person-years (95% CI -55.0 to -24.4); NNT 76).
“For safety outcomes, SGLT2i vs DPP4i initiators with dementia showed less acute kidney injury (IRD -39.7 [-55.0, -24.4]; NNT: 76)”
Humanspeople with dementia, versus DPP4 inhibitorsn = 2,481
Caloric restriction decreases acute kidney injury in humans (preoperative formula diet before cardiac surgery) (41.7% in CR group vs 47.5% in control group; reduced by 5.8%).
“Incidence of acute kidney injury was reduced by 5.8% (41.7% in the CR group compared with 47.5% in the control group).”
Human trialpreoperative formula diet before cardiac surgeryformula diet60% of the daily energy requirement7 days before surgeryn = 82
Caloric restriction prevents acute kidney injury in ovary-intact animals with AKI.
“The present study indicated that CR is more effective than TR in preventing AKI, probably by increasing SIRT1 and decreasing TGF-β1 in ovary-intact animals.”
Animalsin ovary-intact animals with AKI8 weeksfemales
Caloric restriction protects against acute kidney injury in mice (ischemia reperfusion injury).
“Kidney ischemia reperfusion injury robustly induced acute kidney injury in male mice and this damage could be markedly attenuated by pretreatment with caloric restriction.”
GLP-1 receptor agonists are linked with lower acute kidney injury in humans (preoperative use before nephrectomy; propensity-matched cohort) (OR 0.76).
“Those on GLP-1RA therapy had significantly lower odds of 90-day AKI (OR = 0.76; P = .031)”
Humanspreoperative use before nephrectomy; propensity-matched cohort90 days
GLP-1 receptor agonists are linked with lower acute kidney injury in humans (patients with T2DM and ESRD compared with matched non-users) (10.45% vs. 14.04%, OR 0.715, CI 0.591-0.865).
“The rate of AKI was lower in the patients receiving GLP-1 receptor agonists (10.45% vs. 14.04%, OR 0.715, CI 0.591-0.865, p = 0.0005).”
Humanspatients with T2DM and ESRD compared with matched non-usersat least 6 months of therapyn = 2,009
Empagliflozin showed no clear effect on acute kidney injury in humans.
“There were no statistically significant differences between groups in genitourinary tract infections, life-threatening infections, in-hospital mortality, length of hospitalization, or acute kidney injury.”
Human trialPatients undergoing elective isolated coronary artery bypass grafting; compared with placebo10 mg once dailyn = 467
Physiology-guided complete revascularization showed no clear effect on acute kidney injury in humans (older MI patients with multivessel disease) (HR: 1.11; 95% CI: 0.87-1.43).
“Contrast-associated acute kidney injury occurred in 245 patients (17%), increased progressively across Kidney Disease: Improving Global Outcomes (KDIGO) stages (P < 0.001), and was similar between treatment arms (HR: 1.11; 95% CI: 0.87-1.43).”
Human trialolder MI patients with multivessel disease
Anti-obesity medications showed no clear effect on acute kidney injury in humans (weight reduction mediated by AOMs vs placebo) (RR 0.98 (95% CI 0.78 to 1.21)).
Acute kidney injury is linked with higher mortality in humans (post-AKI survivors who recovered renal function) (HR = 3.375; 95% CI 2.241-5.083; P < 0.001).
“mortality at 12 month was higher in the patient with recurrent AKI as compared with those with a single episode (HR = 3.375; 95% CI 2.241-5.083; P < 0.001).”
Humanspost-AKI survivors who recovered renal function12 months
Absolute and relative intraoperative hypotension thresholds
↔no changein humans1
1 study
Absolute and relative intraoperative hypotension thresholds were not clearly linked with acute kidney injury in humans (Patients undergoing hip fracture surgery).
“Absolute and relative IOH thresholds were not significantly associated with outcomes.”
HumansPatients undergoing hip fracture surgery69.8% femalesn = 473
SGLT2 inhibitors are associated with acute kidney injury in humans (Type 2 diabetes; compared with DPP-4 inhibitors after propensity score matching) (8.4% vs 9.9%; risk ratio 0.853, 95% CI 0.839–0.868).
“Renal outcomes showed lower acute kidney injury (AKI) with SGLT2i (8.4% vs 9.9%; risk ratio 0.853, 95% CI 0.839-0.868; HR 0.768)”
HumansType 2 diabetes; compared with DPP-4 inhibitors after propensity score matching5 years
SGLT2 inhibitors are linked with a lower risk of acute kidney injury in humans (Type 2 diabetes; compared with DPP-4 inhibitor initiation) (HR 0.76, 95% CI 0.60-0.95).
“SGLT2i initiation was associated with lower risks of acute kidney injury (HR 0.76, 95% CI 0.60-0.95)”
HumansType 2 diabetes; compared with DPP-4 inhibitor initiation
SGLT2 inhibitors are associated with acute kidney injury in humans (LVAD recipients without diabetes receiving contemporary GDMT) (HR 0.47–0.51).
“adjunctive SGLT2 inhibitor therapy was associated with significantly lower mortality, acute kidney injury, and sepsis across short- and intermediate-term follow-up”
HumansLVAD recipients without diabetes receiving contemporary GDMT2 years
SGLT2 inhibitors are associated with acute kidney injury in humans (Type 2 diabetes mellitus; compared with DPP-4 inhibitors) (HR 0.55, 95% CI 0.51–0.59).
SGLT2 inhibitors are linked with a higher risk of acute kidney injury in humans (propensity-matched adults aged 80 years or older with chronic kidney disease).
“Risk of acute kidney injury was higher in the SGLT2i group”
Humanspropensity-matched adults aged 80 years or older with chronic kidney diseasetwo yearsn = 10,076
SGLT2 inhibitors are associated with acute kidney injury in humans (type 2 diabetes mellitus following hospitalization for pneumonia) (RR 0.89, 95% CI 0.84–0.94).
“AKI (RR: 0.89, 95% CI: 0.84-0.94, p < 0.0001)”
Humanstype 2 diabetes mellitus following hospitalization for pneumonian = 6,505
Acute kidney injury is linked with a higher risk of mortality in humans (postoperative) (OR 4.58, 95% CI [4.09, 5.13]).
“acute renal failure (OR: 4.58 95% CI [4.09, 5.13], P < 0.001), pneumonia (95% CI [2.72, 3.83], P < 0.001), and myocardial infarctions (OR: 2.65, 95% CI [1.80, 3.92], P < 0.001) increased likelihood of death after undergoing HHA.”
Frailty is linked with a higher risk of acute kidney injury in humans (undergoing transcatheter edge-to-edge repair for severe mitral regurgitation) (OR 15.91, [13.49-18.77]).
“AKI (OR 15.91, [13.49-18.77], P<0.001)”
Humansundergoing transcatheter edge-to-edge repair for severe mitral regurgitationn = 27,062
GLP-1 receptor agonists are associated with acute kidney injury in humans (Use within 12 months before transcatheter aortic valve replacement) (17.9% vs 22.9%; RR 0.78).
“Pre-procedural GLP-1 RA use was associated with decreased risks of myocardial infarction, acute kidney injury, and all-cause mortality following TAVR.”
HumansUse within 12 months before transcatheter aortic valve replacement
GLP-1 receptor agonists are associated with acute kidney injury in humans (Schizophrenia, BMI ≥27 kg/m2, and antipsychotic use; compared with non-users) (HR 0.71, 95% CI 0.67–0.75).
“lower hazards of MI (HR 0.75, 95% CI 0.68-0.82), stroke (HR 0.85, 95% CI 0.78-0.93), HF (HR 0.89, 95% CI 0.85-0.93), revascularization (HR 0.86, 95% CI 0.77-0.97), AKI (HR 0.71, 95% CI 0.67-0.75)”
HumansSchizophrenia, BMI ≥27 kg/m2, and antipsychotic use; compared with non-users3 years
GLP-1 receptor agonists are associated with acute kidney injury in humans (Type 2 diabetes; compared with DPP-4 inhibitors) (8.5% vs 9.4%; RR 0.911; HR 0.815).
“Renal outcomes showed lower acute kidney injury (8.5% vs 9.4%; risk ratio 0.911; HR 0.815)”
HumansType 2 diabetes; compared with DPP-4 inhibitors5 years
GLP-1 receptor agonists are associated with acute kidney injury in humans (Non-obese, non-diabetic MASLD; sustained users compared with matched non-users) (HR 0.46, 95% CI 0.26–0.81).
“sustained GLP-1 RA use was associated with lower cardiovascular and renal event rates but not with hepatic events.”
HumansNon-obese, non-diabetic MASLD; sustained users compared with matched non-usersFive years
GLP-1 receptor agonists are linked with a lower risk of acute kidney injury in humans (older adults with pulmonary hypertension, compared with SGLT2I therapy) (0.792 [0.731-0.857]).
“GLP1A use was associated with reduced risk of AKI (0.792 [0.731-0.857])”
Humansolder adults with pulmonary hypertension, compared with SGLT2I therapy
American Journal of Respiratory and Critical Care Medicine·
GLP-1 receptor agonists are linked with a lower risk of acute kidney injury in humans (obese patients with metformin-treated type 2 diabetes undergoing TKA) (OR 0.755; P = 0.021).
“GLP-1RA use was associated with notable reductions in postoperative anemia (odds ratio [OR] 0.714; P = 0.001), acute kidney injury (OR 0.755; P = 0.021)”
Humansobese patients with metformin-treated type 2 diabetes undergoing TKAn = 8,170
GLP-1 receptor agonists are linked with a lower risk of acute kidney injury in humans (T2DM patients undergoing partial nephrectomy for RCC) (OR = 0.712, p < 0.05).
“Use of GLP-1RAs was associated with lower odds of acute kidney injury (odds ratio [OR] = 0.712)”
HumansT2DM patients undergoing partial nephrectomy for RCC
Semaglutide is associated with acute kidney injury in humans (Heart failure with reduced ejection fraction and obesity; compared with no GLP-1 RA use) (HR 0.62; 95% CI 0.58–0.67).
“Additional significant associated reductions were observed for AKI (HR 0.62; 95% CI 0.58-0.67)”
HumansHeart failure with reduced ejection fraction and obesity; compared with no GLP-1 RA use365 days
Semaglutide is linked with a lower risk of acute kidney injury in humans (30 days after COVID-19 or influenza infection) (COVID-19 RR 0.56; flu RR 0.54).
“and acute kidney injury (COVID-19 RR 0.56; flu RR 0.54) in the 30-day observation period”
Humans30 days after COVID-19 or influenza infectionkidney30 days
Semaglutide is linked with a higher risk of acute kidney injury in humans (propensity-matched comparison with tirzepatide in HFpEF and obesity) (7.0% vs 6.2%; OR 1.14).
“Acute kidney injury was also slightly higher in the Semaglutide group (7.0% vs 6.2%; OR 1.14, p=0.016)”
Humanspropensity-matched comparison with tirzepatide in HFpEF and obesityn = 40,047
African journal of thoracic and critical care medicine·
Acute kidney injury is linked with a higher risk of in-hospital mortality in humans (multimorbid medical hospitalisations) (14.4% vs 4.4%, aOR 2.56 [95% CI 2.52-2.61]).
“for the AKI group 14.4% (adjusted odds ratio [aOR] 2.56 [95% CI 2.52-2.61])”
Acute kidney injury raises the risk of chronic kidney disease (when repair is unsuccessful (failed repair)).
“In instances where repair is unsuccessful, the kidney experiences maladaptive alterations that may progressively result in chronic kidney disease (CKD), a phenomenon referred to as failed repair.”
Reviewwhen repair is unsuccessful (failed repair)kidney
Frailty is linked with a higher risk of acute kidney injury in humans (liver transplant recipients).
“It was also associated with higher risks of acute kidney injury, prolonged mechanical ventilation, vasopressor requirement/hemodynamic instability, renal replacement therapy”
older age is linked with a higher risk of acute kidney injury in humans (hospitalized patients aged 65 years or older compared with younger patients) (incidence 15.44% (65-79 years) and 22.22% (80 years and older)).
“AKI incidence, in-hospital mortality, percentage of patients requiring dialysis and percentage without renal recovery were higher in elderly patients than in younger patients.”
Humanshospitalized patients aged 65 years or older compared with younger patientsn = 42,737
Dapagliflozin lowers the risk of acute kidney injury in humans following elective cardiac surgery (28% vs 52%).
“Compared with placebo, dapagliflozin reduced the incidence of AKI (28% vs 52%; relative risk, 0.54 [95% CI, 0.45-0.65]; P < .001) over 7-day follow-up after surgery.”
Human trialfollowing elective cardiac surgerykidney10 mg orally once daily4 dosesn = 784
Diabetes mellitus raises the risk of acute kidney injury in humans (hospitalised, multimorbid) (p < 0.05).
“Both prevalent and incident symptomatic hypoglycaemia and incident acute kidney injury (AKI) were significantly more common in people with diabetes (p < 0.05).”
Testosterone raises the risk of acute kidney injury in humans (hypogonadism and preexisting or high risk of cardiovascular disease).
“A higher incidence of atrial fibrillation, of acute kidney injury, and of pulmonary embolism was observed in the testosterone group.”
Human trialhypogonadism and preexisting or high risk of cardiovascular disease1.62% geldose adjusted to maintain testosterone levels between 350 and 750 ng per deciliter21.7±14.1 monthsmalesn = 5,246
National Institute of Diabetes and Digestive and Kidney Diseases$13.3MFood and Drug Administration$350KGouvernement du Canada | Canadian Institutes of Health ResearchCA$830K
Acute kidney injury is linked with higher mortality in hospitalized very old adults, while human studies associate frailty with higher injury risk after cardiac surgery and clonal hematopoiesis with higher injury risk. Nicotinamide mononucleotide protects mice against cisplatin-induced kidney injury, but a human trial shows no clear effect on acute kidney injury.
Summary rewritten as its findings changed.
As it read before
Human observational studies associate frailty and PhenoAge acceleration with acute kidney injury and link injury to higher mortality in older patients. SGLT2 inhibitors are associated with lower risk in older adults with diabetes and dementia but higher risk in rheumatic heart disease. Nicotinamide mononucleotide protects mice in induced injury models but does not reduce injury in a human trial.
Summary rewritten as its findings changed.
As it read before
Human studies link acute kidney injury to frailty, PhenoAgeAccel and clonal hematopoiesis of indeterminate potential. Trials report reduced risk with SGLT2 inhibitors in type 2 diabetes, while observational studies report lower, unchanged or higher risk across clinical populations. A mouse study reports less injury with P2RX7 antagonism in septic and aging mice, and reviews link injury to cellular senescence and dementia.
Among survivors off dialysis for 90 days, moderate to severe frailty was linked to higher mortality than being fit, with an adjusted hazard ratio of 1.17.Among survivors off dialysis for 90 days, moderate to severe frailty was linked to higher mortality than being fit, with an adjusted hazard ratio of 1.17.